Neutrocyte-to-lymphocyte ratio predicts the presence of a replicative hepatitis C virus strand after therapy with direct-acting antivirals
Tóm tắt
Residual HCV-RNA can persist in liver tissue and peripheral blood mononuclear cells (PBMCs) long after antiviral therapy of chronic hepatitis C in patients repeatedly negative for viral RNA in serum. This occult infection associates with impaired immune response and the risk of lymphoproliferative disorders or progressive liver disease. There are currently no monitoring strategies for patients after treatment. We investigated if serum inflammation markers and interferon lambda (IFNL) genotype can be predictors of the presence of HCV-RNA and the replicative HCV-RNA (−) strand in patients who reached sustained virological response after interferon-free therapy. Forty-two consecutive patients who remained HCV-RNA negative in serum 24 weeks after the end of treatment (EOT) and during the follow-up were enrolled. Total HCV-RNA and HCV-RNA (−) strand were detected using ultrasensitive RT-PCR in PBMCs collected 12–15 months after EOT. Polymorphisms within IFNL3–IFNL4 region (rs12979860 and ss469415590) were genotyped with allele-specific PCR. Viral RNA was found in PBMCs from 31 (74%) patients, and of those 29 (69%) were also positive for HCV-RNA (−). Neither normalization of alanine aminotransferase nor IFNL genotype predicted the presence of residual HCV-RNA. A significantly higher neutrocyte-to-lymphocyte ratio (NLR) 24 weeks after the start of treatment predicted elimination of replicative HCV-RNA strand (OR 0.23; 95% CI 0.10–0.86; P = 0.019). Patients with no HCV-RNA (−) in PBMCs showed a greater increase in neutrocyte count between EOT and baseline (P = 0.028). Lack of significant elevation of NLR after therapy with direct-acting antivirals could predict the presence of residual replicative HCV-RNA strand in PBMCs.
Tài liệu tham khảo
Pham TN, Michalak TI. Occult hepatitis C virus infection and its relevance in clinical practice. J Clin Exp Hepatol. 2011;1:185–9.
Chen CL, Huang JY, Wang CH, et al. Hepatitis C virus has a genetically determined lymphotropism through co-receptor B7.2. Nat Commun. 2017;8:13882.
Skardasi G, Chen AY, Michalak TI. Authentic patient-derived hepatitis C virus infects and productively replicates in primary CD4 + and CD8 + T lymphocytes in vitro. J Virol. 2018;92:e01790-17.
Kondo Y, Shimosegawa T. Direct effects of hepatitis C virus on the lymphoid cells. World J Gastroenterol. 2013;19:7889–95.
Dai B, Chen AY, Corkum CP, et al. Hepatitis C virus upregulates B-cell receptor signaling: a novel mechanism for HCV-associated B-cell lymphoproliferative disorders. Oncogene. 2016;35:2979–90.
Roque-Cuéllar MC, Sánchez B, García-Lozano JR, et al. Hepatitis C virus-specific cellular immune responses in sustained virological responders with viral persistence in peripheral blood mononuclear cells. Liver Int. 2014;34:e80–8.
Radkowski M, Opoka-Kegler J, Cortes KC, et al. Evidence for immune activation in patients with residual hepatitis C virus RNA long after successful treatment with IFN and ribavirin. J Gen Virol. 2014;95:2004–9.
Attar BM, Van Thiel DA. New twist to a chronic HCV infection: occult hepatitis C. Gastroenterol Res Pract. 2015;2015:579147.
Gambato M, Pérez-del-pulgar S, Hedskog C, et al. Hepatitis C virus RNA persists in liver explants of most patients awaiting liver transplantation treated with an interferon-free regimen. Gastroenterology. 2016;151:633–6.
Elmasry S, Wadhwa S, Bang B-R, et al. Detection of occult hepatitis C virus infection in patients who achieved a sustained virologic response to direct-acting antiviral agents for recurrent infection after liver transplantation. Gastroenterology. 2017;152:550–3.
Wróblewska A, Bernat A, Woziwodzka A, et al. Interferon lambda polymorphisms associate with body iron indices and hepatic expression of interferon-responsive long non-coding RNA in chronic hepatitis C. Clin Exp Med. 2017;17:225–32.
Kato T, Date T, Miyamoto M, et al. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology. 2003;125:1808–17.
Pham TNQ, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol. 2004;78:5867–74.
Radkowski M, Horban A, Gallegos-Orozco JF, et al. Evidence for viral persistence in patients who test positive for anti-hepatitis C virus antibodies and have normal alanine aminotransferase levels. J Infect Dis. 2005;191:1730–3.
Prokunina-Olsson L, Muchmore B, Tang W, et al. A variant upstream of IFNL3 (IL28B) creating a novel interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013;45:164–71.
Rosenberg BR, Freije CA, Imanaka N, et al. Genetic variation at IFNL4 influences extrahepatic interferon-stimulated gene expression in chronic HCV patients. J Infect Dis. 2017;217:650–5.
Ramamurthy N, Marchi E, Ansari MA, et al. Impact of IFNL4 genotype on interferon-stimulated gene expression during DAA therapy for hepatitis C. Hepatology. 2018;68:859–71.
Bartolomé J, Castillo I, Quiroga JA, Carreño V. Interleukin-28B polymorphisms and interferon gamma inducible protein-10 serum levels in seronegative occult hepatitis C virus infection. J Med Virol. 2016;88:268–74.
Miri SM, Sharafi H, Pouryasin A, et al. The role of polymorphisms Near IFNL3 gene as predictors of residual HCV RNA in buffy coat after successful antiviral therapy. Hepat Mon. 2017;17:e12301.
Angulo J, Pino K, Pavez C, et al. Genetic variations in host IL28B links to the detection of peripheral blood mononuclear cells–associated hepatitis C virus RNA in chronically infected patients. J Viral Hepat. 2013;20:263–72.
Meng X, Wei G, Chang Q, et al. The platelet-to-lymphocyte ratio, superior to the neutrophil-to-lymphocyte ratio, correlates with hepatitis C virus infection. Int J Infect Dis. 2016;45:72–7.
Purnak T, Olmez S, Torun S, et al. Mean platelet volume is increased in chronic hepatitis C patients with advanced fibrosis. Clin Res Hepatol Gastroenterol. 2013;37:41–6.
Casadei Gardini A, Foschi FG, Conti F, Petracci E, Vukotic R, Marisi G. Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. Dig Liver Dis. 2018. https://doi.org/10.1016/j.dld.2018.09.016.
Debes JD, van Tilborg M, Groothuismink ZMA, et al. Levels of cytokines in serum associate with development of hepatocellular carcinoma in patients with HCV infection treated with direct-acting antivirals. Gastroenterology. 2018;154:515–7.
Casadei Gardini A, Conti A, Brillanti F, et al. Imbalance of neutrophils and lymphocyte counts can be predictive of hepatocellular carcinoma occurrence in hepatitis C-related cirrhosis treated with direct-acting antivirals. Gastroenterology. 2018;154:2281–2.
Meissner EG, Wu D, Osinusi A, et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest. 2014;124:3352–63.
Alao H, Cam M, Keembiyehetty C, et al. Baseline intrahepatic and peripheral innate immunity are associated with hepatitis C virus clearance during direct-acting antiviral therapy. Hepatology. 2018;68:2078–88.